Schedule One - Roquefort Therapeutics PLC

AI SummaryClose X

Roquefort Therapeutics plc will be renamed Coiled Therapeutics plc upon its readmission to AIM on March 27, 2026, following the acquisition of the AO-252 Licence from A2A Pharmaceuticals for approximately £31.90 million, satisfied by the issue of shares. The company is raising £8.5 million at 10 pence per share, anticipating a market capitalization of £42.6 million. The AO-252 molecule, a novel inhibitor targeting TACC3 protein-protein interactions, has shown strong preclinical efficacy in various cancers and is currently in a Phase I trial in the USA with encouraging results and a benign safety profile. The company's main country of operation will shift to the USA post-readmission.

Disclaimer*

UK 100

Latest directors dealings